Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 3

2(33.3%)

Phase 2

1(16.7%)

6Total

N/A(3)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01765517Not ApplicableCompleted

Study to Explore the Effects of Probiotics on Endotoxin Levels in Type 2 Diabetes Mellitus Patients

Role: collaborator

NCT02874521Not ApplicableCompleted

Low-frequency Electrical Muscle Stimulation vs Cycle Training During Haemodialysis

Role: collaborator

NCT00838656Phase 2Unknown

Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Role: lead

NCT00720070Phase 3Unknown

PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer

Role: lead

NCT00945204Not ApplicableCompleted

Evaluation of Intermediate Care Clinics for Diabetes

Role: collaborator

NCT00712140Phase 3Unknown

Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer

Role: lead

All 6 trials loaded